Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1, Type 1 Diabetes
Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
This study has been designed as a prospectively enrolled, randomized sequence, 2-way crossover study of device performance, tolerability and safety of an investigational insulin infusion set using a coil-reinforced soft polymer…
- Trial name
- NCT04398030
- Testing
- coil-reinforced soft polymer indwelling cannula, soft Teflon indwelling catheter
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Capillary Biomedical, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 1 Diabetes Mellitus
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks.
- Trial name
- NCT02897219
- Testing
- ipragliflozin, Insulin Therapy
- Where
- 36 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Astellas Pharma Inc
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
Primary Objective: To assess the relative bioavailability of sotagliflozin following single doses of 3 sotagliflozin prototype tablet formulations p1, p2 and p3 versus the reference tablet formulation in fasted conditions in…
- Trial name
- NCT03310944
- Testing
- sotagliflozin (SAR439954)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 1 Diabetes
Insulet Artificial Pancreas Early Feasibility Study
The purpose is to perform an early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the OmniPod® Insulin Management System and gather clinical data that will be used to make…
- Trial name
- NCT02897557
- Testing
- Insulet Artificial Pancreas (AP) System
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Insulet Corporation
Diabetic Polyneuropathy
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
- Trial name
- NCT00878293
- Testing
- GRT6005, MS Continus®
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 90 people
- Sponsor
- Tris Pharma, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes
This trial is conducted in Asia and Oceania. The aim of this trial is to compare the efficacy and safety of human insulin produced by the current process and the NN729 process in type 1 diabetes.
- Trial name
- NCT00569400
- Testing
- human insulin
- Where
- 15 sites in Australia, Hong Kong and 2 more
- Volunteers
- 241 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Healthy Subjects
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal…
- Trial name
- NCT03802487
- Testing
- Sotagliflozin (SAR439954), 14C-microtracer, Charcoal
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Of Three PF-05190457 Formulations In Healthy Volunteers
The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.
- Trial name
- NCT01522807
- Testing
- PF-05190457
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study.
- Trial name
- NCT01134107
- Testing
- Insulin Lispro 6 Day (6D), Insulin Aspart 6 Day (6D)
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 1 Diabetes
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
- Trial name
- NCT04450407
- Testing
- LY3209590, Insulin Degludec
- Where
- 54 sites in United States, Austria and 3 more
- Volunteers
- 266 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use…
- Trial name
- RECORD-IQ (NCT07211126)
- Testing
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Where
- 25 sites in France
- Volunteers
- 350 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Type2 Diabetes, Type1diabetes
Accuracy Characterization Study
To demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring System (System) interstitial glucose results against venous glucose reference and capillary fingerstick using the Consensus Error Grid over the wear…
- Conditions
- Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
- Trial name
- ACS (NCT01932944)
- Testing
- No treatment
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott Diabetes Care
Diabetes, Diabetes Mellitus, Type 1
Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes
This trial is conducted in Africa, Europe and Oceania. The aim of this trial is to investigate whether insulin detemir combined with insulin aspart compared to NPH insulin combined with insulin aspart could reduce the frequency…
- Trial name
- NCT01697657
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 11 sites in Australia, Croatia and 4 more
- Volunteers
- 131 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and tolerability of pioglitazone-azilsartan, once daily (QD), in patients with type 2 diabetes mellitus.
- Trial name
- NCT01124656
- Testing
- Pioglitazone-Azilsartan
- Volunteers
- 26 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01924637
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.